Yes, it may look like mindless drifting and messing about in the new, 903-horserpower, $1.3-million McLaren P1, but we’re sure there’s some kind of work going on here.
Janssen R&D Ireland (Janssen) have announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81...
Satori™ Pharmaceuticals announced the presentation of two posters at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) taking place in Paris, France, July 16-21, 2011. Both posters illuminate the unique biological activity associated with Satori's approach to the...
When the Centers for Medicare & Medicaid Services (CMS) initiated its Physician Group Practice (PGP) Demonstration, it challenged the 10 participating large physician group practices to prove that providing high quality coordinated health care could also save money. CMS, part of the U.S...
Demonstrating unmatched leadership in molecular imaging, Siemens Healthcare presents its leading portfolio in hybrid imaging solutions with molecular CT and molecular MR at the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 to...
Thanksgiving is in some ways the best holiday because it is all about ... gravy. But when you dig a little you find racism and religiosity and other icky stuff. Here's an example of what can go wrong:
Read the comments on this post...
More...
Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide...
Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of results from a study showing that PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN® (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with...
Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and...
Nektar Therapeutics (Nasdaq: NKTR) presented promising data from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects...
Ethicon Endo-Surgery, Inc. (EES), a leader in surgical technology, will showcase the company's recent innovations and preview future advancements in surgery at the 96th Annual Clinical Congress of the American College of Surgeons (ACS) in Washington D.C. this week. The new products represent the...
QRxPharma Limited has announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in...
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed...
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed...
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed...
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed...
A recent study led by MedImpact Healthcare Systems, Inc., investigated a pilot Value-Based Benefit Design (VBBD) program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36% reduced the number of non-adherent...
A recent study led by MedImpact Healthcare Systems, Inc., investigated a pilot Value-Based Benefit Design (VBBD) program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36% reduced the number of non-adherent...
A recent study led by MedImpact Healthcare Systems, Inc., investigated a pilot Value-Based Benefit Design (VBBD) program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36% reduced the number of non-adherent...
An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General...